PubMed ID:
21835294
Public Release Type:
Journal
Publication Year: 2011
Affiliation: Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA 94304, USA. tichang@stanford.edu
DOI:
https://doi.org/10.1016/j.ahj.2011.05.004
Authors:
Chang TI,
Winkelmayer WC,
Chertow GM,
Cheung AK,
Brunelli SM,
Shilane D
Request IDs:
648
Studies:
Hemodialysis Study
Persons with end-stage renal disease (ESRD) on hemodialysis carry an exceptionally high burden of cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEIs) are recommended for patients on dialysis, but there are few data regarding their effectiveness in ESRD.